Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial. - Wikidata - awgldk - TriplyDB

Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial.

Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial.

http://www.wikidata.org/entity/Q34600950

about

Regulation of adaptive immunity; the role of interleukin-10 Modulation of deregulated chaperone-mediated autophagy by a phosphopeptide Antigen-based immunotherapy for autoimmune disease: current status The Spliceosomal Phosphopeptide P140 Controls the Lupus Disease by Interacting with the HSC70 Protein and via a Mechanism Mediated by γδ T Cells HSPA8/HSC70 chaperone protein: structure, function, and chemical targeting.Human platelet antigen (HPA)-1a peptides do not reliably suppress anti-HPA-1a responses using a humanized severe combined immunodeficiency (SCID) mouse model.Treating human autoimmunity: current practice and future prospects Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.Peptides and peptidomimetics as immunomodulators.Epigenetics of autoantigens: new opportunities for therapy of autoimmune diseases.The importance of implementing proper selection of excipients in lupus clinical trials Murine models of systemic lupus erythematosus HSC70 blockade by the therapeutic peptide P140 affects autophagic processes and endogenous MHCII presentation in murine lupus.The U1-snRNP complex: structural properties relating to autoimmune pathogenesis in rheumatic diseases.Tetramers reveal IL-17-secreting CD4+ T cells that are specific for U1-70 in lupus and mixed connective tissue disease.Manipulating autophagic processes in autoimmune diseases: a special focus on modulating chaperone-mediated autophagy, an emerging therapeutic target.Prophylactic Injection of Recombinant Alpha-Enolase Reduces Arthritis Severity in the Collagen-Induced Arthritis Mice Model Metabolic regulation of organelle homeostasis in lupus T cells Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus.Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects.Drugs in early clinical development for Systemic Lupus Erythematosus.Conservation of pathogenic TCR homology across class II restrictions in anti-ribonucleoprotein autoimmunity: extended efficacy of T cell vaccine therapy.Glomerular antibodies in lupus nephritis.Antigen-specific immunotherapy of autoimmune and allergic diseases Balancing efficacy and toxicity of novel therapies in systemic lupus erythematosus.Is there a cure for systemic lupus erythematosus?Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies.Emerging view of autophagy in systemic lupus erythematosus.Emerging biological therapies for systemic lupus erythematosus.Multifunctional adamantane derivatives as new scaffolds for the multipresentation of bioactive peptides.Resetting the autoreactive immune system with a therapeutic peptide in lupus.Nanomaterials, Autophagy, and Lupus Disease.Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art.Emerging therapies in systemic lupus erythematous: from clinical trial to the real life.Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials.Update on Biologic Therapies for Systemic Lupus Erythematosus.Autophagy: controlling cell fate in rheumatic diseases.Optimization of current and future therapy for autoimmune diseases.

P2860

Q21131215-1F14D60E-0000-4990-BFA3-1B713238CF09 Q24320133-2F054754-ADD7-441D-A1BE-0189742002B3 Q26852915-B99B7B46-6EBD-44D9-B6EC-D0EAEFC4A5CC Q27655180-79D2DE63-A4B1-40FB-92B6-2D6074E075A5 Q30354473-B09A352F-F4AC-4899-A963-D95238DADB72 Q33411662-7067F856-E058-46F7-AF12-50618A5351CA Q33772444-DFFE1D1C-A7C8-48D1-88AD-9B8AFB403A00 Q34128422-92574705-6BE8-410F-A6D6-9F74165AD069 Q34245983-09656F1B-CD34-4DDC-B394-8ECB53114A1D Q34359984-0CD70692-BA45-4236-9873-E9FC1AB3616D Q34463063-C328F088-BFFE-4909-923C-898A69FEBEEA Q34512785-02EA599F-C0A8-41DB-BE37-9A420A5D362E Q34591019-7DA9330F-6C30-49C0-9B8D-7CABE7C323DD Q34625909-511E13DA-A6A0-4094-9F66-38AA2D2EDEAB Q34779998-7A94434F-14CD-400B-8E87-84E1BAE96743 Q35189911-B523F3AC-C31F-4698-AEFC-BEA36FF0F7EB Q35622999-576EB922-00D4-4EE0-82C5-D4E10274479E Q35753838-C0004CB0-FEAA-475C-9E83-FE25FE2A5A3C Q36177195-790288D6-F7CC-4023-8338-F380B2E2A4B4 Q37150868-7C3A2BEE-0449-4A6F-9F62-29141D11C22C Q37267547-AB976B6A-EE3A-4A49-8341-9D555893C816 Q37270803-264159AD-E276-4E2B-81FF-445C714A2B22 Q37324772-7C9EE53E-5635-4D5B-B646-1EBF40E6501E Q37726019-647095FC-B3DD-448C-B912-F0B5F1DC986D Q37736310-46C571BC-33F3-4F97-9A67-6E3C5143A62B Q37790023-5BCEB3EE-E876-4694-8DF5-8FDD3C0C0CAD Q37960525-56405348-5CCA-4311-ADC2-A70585CC7619 Q38095888-3FF181A2-AADB-456E-A5D0-025C3BCB1D72 Q38175493-031DE5E0-3FD5-4594-921F-686B55201816 Q38189443-BFDA041D-2BB3-4E46-B67B-4D92126BB283 Q38192683-EBE30813-44BC-4C0F-BEC4-FB1A6170D6F1 Q38275427-81B776B7-B605-41E6-9EAE-ADC8F7314547 Q38388415-850E502A-A8CF-4C1B-AEFC-53DD83215765 Q38551098-815A3B07-A934-4FFB-AF45-65FA19E8930D Q38690844-D7711A10-E99C-44C2-9A33-033BF523A4FA Q38747383-B391E05B-A77C-4B07-9050-2DF23730A419 Q38840646-C87CA942-3191-4A59-A174-60B121EFD143 Q38864797-8304C0D8-DBB7-45EA-8DB8-5BB4C0EB50CB Q38873681-94314416-016F-4A7C-A525-CA54BE2AA9D1 Q39666645-D924823C-ACBB-4443-A01A-7E5D1526978A

P2860

Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial.

http://www.wikidata.org/entity/Q34600950

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Spliceosomal peptide P140 for ...... early phase II clinical trial.

@ast

Spliceosomal peptide P140 for ...... early phase II clinical trial.

@en

Spliceosomal peptide P140 for ...... early phase II clinical trial.

@nl

type

label

Spliceosomal peptide P140 for ...... early phase II clinical trial.

@ast

Spliceosomal peptide P140 for ...... early phase II clinical trial.

@en

Spliceosomal peptide P140 for ...... early phase II clinical trial.

@nl

prefLabel

Spliceosomal peptide P140 for ...... early phase II clinical trial.

@ast

Spliceosomal peptide P140 for ...... early phase II clinical trial.

@en

Spliceosomal peptide P140 for ...... early phase II clinical trial.

@nl

P1433

Q34600950-C46A2C06-AF53-47F2-8659-E59E249934B5

P1476

Q34600950-B13951C6-C5C3-4309-BD10-BE6C90EC524A

P2093

Q34600950-038304E9-5831-4903-983C-91D359DE7592

Q34600950-0BEC3E86-736B-433D-8240-E8AD95AE913A

Q34600950-18C28F18-6801-4510-B31D-0E121737AED3

Q34600950-37CE9E14-6A3A-4382-9D84-D7D201D7F039

Q34600950-3EDBC08C-F597-4692-B99B-CEB4934E2105

Q34600950-6AE1C07F-E4F0-4B4E-A328-50DA3B4514D2

Q34600950-974A5800-211D-4D60-BE50-A7F25D868AB7

Q34600950-A2D4C4C8-EBC3-41DF-B8D1-36907F7A9776

P2860

Q34600950-0DEDF433-2259-4881-B35D-BDC6AB84BB39

P304

Q34600950-E2A1FBF7-7609-4B63-ADD0-BB3E998FFD90

P31

Q34600950-B65D6CDE-E870-402B-8AD5-EC42E7D15552

P356

Q34600950-28FB3491-8A3C-4687-BBA3-A186248D4BFC

P433

Q34600950-6960EFBA-F36F-45A0-A9ED-3CDF2C037891

P478

Q34600950-97D22E39-72B7-4936-9295-AA7CA87A64CC

P577

Q34600950-34DAC405-804A-4458-B0A8-92388EFEA284

P5875

Q34600950-87E33EE8-C9B6-4057-860E-5250FAFC490C

P698

Q34600950-E21E445B-BC34-488C-B18F-5BE6E8999A04

P921

Q34600950-08458925-476A-49CA-8974-5129C7CF0710

Q34600950-6C33156A-98E5-4CA3-A4BB-C81725954E32

Q34600950-79BFAE37-A76C-4FE8-9883-2CD34EB3EA09

P356

P1433

Arthritis & Rheumatology

P1476

Spliceosomal peptide P140 for ...... early phase II clinical trial.

@en

P2093

Boycho A Oparanov

http://www.w3.org/2001/XMLSchema#string

Fanny Monneaux

http://www.w3.org/2001/XMLSchema#string

Jean-Marie Geiger

http://www.w3.org/2001/XMLSchema#string

Nicolas Schall

http://www.w3.org/2001/XMLSchema#string

Philippe Wiesel

http://www.w3.org/2001/XMLSchema#string

Rasho K Rashkov

http://www.w3.org/2001/XMLSchema#string

Robert Zimmer

http://www.w3.org/2001/XMLSchema#string

Sylviane Muller

http://www.w3.org/2001/XMLSchema#string

P2860

Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+ T cell suppressors.

P304

3873-3883

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.24027

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23499311

http://www.w3.org/2001/XMLSchema#string

P698

19035498

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial